Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Chosa

    MCap

    SEK57m

    Last close

    SEK0.80

    ▲ 0.20 (33.33%)

    Vection Technologies

    MCap

    AUD47m

    Last close

    AUD0.04

    ▲ 0.00 (12.90%)

    Metro Bank

    MCap

    GBP684m

    Last close

    GBP1.02

    ▲ 7.90 (8.43%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Medlab Clinical – executive interview

Medlab Clinical – executive interview

Medlab Clinical — 2 videos in collection

More on this equity

Medlab Clinical is an Australian biotechnology company that is developing therapeutics using its proprietary delivery platform NanoCelle, which enables a convenient buccal spray delivery. Medlab’s lead product is NanaBis, a combination of THC and CBD (1:1) cannabinoids encapsulated in NanoCelle particles that aims to tackle cancer pain management. Importantly, Medlab recently announced that it has successfully produced a synthetic version of NanaBis, which will allow it to move away from a botanical extract.

In this video, Dr Sean Hall, Medlab’s co-founder and CEO, introduces us to Medlab and its lead programmes and discusses what we can expect from this fast-growing company over the coming months.

< Previous
Next >

You may also be interested in these:

Healthcare

Medlab Clinical: Edison Open House Healthcare 2022

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free